Helio Genomics

Healthcare innovation only matters if it can actually reach the patients who need it most. That is the mission behind the Microsoft Rural Health Transformation Collaborative: a large-scale initiative bringing together healthcare, technology, diagnostics, AI, retail health, and community organizations to help improve access, care coordination, chronic disease management, and earlier detection in underserved rural communities across the United States. The program focuses on helping rural healthcare systems deploy implementation-ready solutions including: • AI-powered healthcare infrastructure • Secure cloud and interoperability solutions • Digital patient navigation and engagement tools • Remote monitoring and telehealth capabilities • Population health analytics • Earlier detection and prevention strategies for high-risk patients At Helio Genomics, we are proud to contribute to this collaborative through our work in AI-powered blood-based early liver cancer detection, helping identify patients at risk earlier when treatment options and outcomes may be significantly improved. Liver cancer remains one of the fastest-growing causes of cancer-related deaths in the United States, yet many high-risk patients still do not receive recommended surveillance in time, especially in underserved and rural communities. We believe improving access to earlier detection must be part of the future of rural healthcare transformation. Because where a patient lives should never determine whether cancer is detected early enough to save their life. #RuralHealth #HealthcareInnovation #AI #EarlyDetection #LiverCancer #Diagnostics #DigitalHealth

Meet the team: Dr. Achyut Saroj, Medical Science Liaison & Board-Certified Medical Affairs Specialist 👏 At Helio Genomics, Achyut Saroj, PhD, BCMAS works closely with GI and transplant clinics supporting the integration of HelioLiver into routine surveillance programs for patients at risk of liver cancer. With a strong focus on clinical education and physician collaboration, he helps bridge innovation and real-world patient care. For Achyut, the mission is clear: “At Helio Genomics, we are closing the blind spots in traditional HCC surveillance to ensure that every patient, regardless of disease etiology, has a chance to help detect liver cancer early for curative options. Happy to see that GI and transplant clinics are incorporating the HelioLiver test into their routine surveillance programs.” We’re proud to have team members like Achyut helping expand access to earlier detection and better patient outcomes. #MeetTheTeam #HelioGenomics #HelioLiver #LiverCancer #LiquidBiopsy #MedicalAffairs #PrecisionMedicine

Helio Genomics is proud to announce a strategic commercial partnership with Syneos Health to accelerate nationwide adoption of HelioLiver™, our AI-powered blood test for early liver cancer detection. This partnership represents an important next step in Helio Genomics’ commercial expansion strategy, combining Helio’s breakthrough multi-analyte technology with Syneos Health’s deep commercialization expertise and national field deployment capabilities. Together, we aim to expand physician awareness, strengthen healthcare provider engagement, and improve patient access to liver cancer screening across the United States. Following our recent Quest Diagnostics partnership, Journal of Hepatology publication, and Microsoft collaboration, this marks another major milestone in scaling HelioLiver nationwide. Read the full announcement here: https://lnkd.in/eHpTR2mN #HelioGenomics #HelioLiver #LiverCancer #EarlyDetection #PrecisionMedicine #HealthcareInnovation

Excited to announce our important collaboration with the Rural Health Transformation Collaborative, co-chaired by Microsoft. Helio Genomics, a member of Microsoft for Startups, is proud to contribute to the Rural Health Transformation Collaborative. Together, we are working to expand access to earlier detection for at-risk patients in underserved rural communities. Liver cancer is one of the fastest-growing causes of cancer deaths in the United States, yet the five-year survival rate remains only about 20%, largely because most cases are detected too late. This is a preventable tragedy, but only if we reach patients in time. Today, fewer than 20% of high-risk patients receive recommended surveillance. In rural communities, the challenge is even greater, with long travel distances making consistent screening difficult. Early detection changes outcomes. The CLiMB study, the largest prospective, multicenter U.S. trial of its kind, was published in the Journal of Hepatology on May 6, 2026. It demonstrated that HelioLiver can detect liver cancer at these critical early stages. Through this collaboration, we aim to bring more accessible, effective surveillance approaches directly into rural care settings. Helio Genomics is developing an epigenomic, blood-based solution designed to enable earlier detection of liver cancer and close the gap in access to care. For patients, this is transformative. Earlier detection enables more high-risk individuals with cirrhosis to access life-extending and potentially curative therapies, dramatically improving survival rates and quality of life. Rather than facing limited options in advanced disease, they now have a reliable, simple blood-based tool that gives them a real fighting chance. David Rhew, M.D., Co-Chair of the Rural Health Transformation (RHT) Collaborative and Global Chief Medical Officer & VP of Health and Life Sciences at Microsoft, said: “The RHT Collaborative is designed to create a future where every rural community has access to high-quality, technology-enabled healthcare. By supporting innovative approaches and care models, collaborations like this help improve access and outcomes for the communities that need them most.” As Bharat Tewarie, CEO of Helio Genomics, shared: “For patients in rural communities, this collaboration represents a step toward more accessible early detection and better outcomes.” Every patient at risk deserves that chance. 👉 To learn more about Helio Genomics and our work in early detection: https://heliogenomics.com/ 👉 For more information about the #RHTCollaborative and how it supports U.S. states in achieving rural health goals, please reach out to the RHT Collaborative co-chairs: Kyu Rhee, MD, MPP — National Association of Community Health Centers (NACHC) Brittany Sachdeva — Cibolo Health James Mault, M.D., FACS — BioIntelliSense, Inc. David Rhew, M.D. — Microsoft #RuralHealth #LiverCancer #EarlyDetection #HealthEquity #HelioGenomics #Microsoft

We’re proud to share a major milestone for Helio Genomics. Our study on early detection of liver cancer, based on the CLiMB study evaluating a multi-analyte blood-basedtest, has been accepted for publication in the Journal of Hepatology. This represents years of work and, more importantly, an opportunity to address a real gap in how liver cancer is detected today. For the first time, we will be able to share results from our head-to-head comparison data. Liver cancer remains one of the leading causes of cancer death worldwide, and current screening methods miss many cancers at an early stage. This represents an important step forward in advancing early detection. Read more: https://lnkd.in/e69rCW22

Meet the team: Dr. Shivani Mahajan, Head of Computational Science 👏 Since joining Helio Genomics in 2021, Shivani Mahajan has led the development of AI and machine learning driving our work in early cancer detection, treatment monitoring, and minimal residual disease. She led the development of the bioinformatics pipeline and algorithm behind HelioLiver Dx, our liquid biopsy test for early detection of liver cancer. Under her leadership, HelioLiver Dx achieved strong results in a large prospective clinical study, demonstrating improved sensitivity compared to ultrasound. For Shivani, the impact goes beyond the data. “What’s especially meaningful is hearing from physicians using HelioLiver Dx who are finding cancer earlier than with ultrasound, sometimes even before it’s clearly visible on MRI. That’s when you realize this work is not just science, it’s changing patient outcomes in real time.” At Helio, we’re proud to have leaders like Shivani pushing the boundaries of AI in cancer care. #MeetTheTeam #HelioGenomics #LiquidBiopsy #AIinHealthcare #PrecisionMedicine #WomenInSTEM

Great to see HelioLiver being implemented in clinical practice. Early detection only works when it reaches both physicians and patients at the right moment.

Tomorrow at 3 PM EST: how do we catch liver cancer earlier — before it’s too late? Join our live session on what’s changing in early detection and what it means for clinical practice today. Last chance to join: 👉 https://lnkd.in/esEGdGbV

Starting today, HelioLiver is live across Quest Diagnostics®. This means healthcare providers across the U.S. can now order HelioLiver directly through their existing Quest Diagnostics workflow. No new systems. No added complexity. Just easier access to advanced liver cancer detection. With Quest’s nationwide network of patient service centers and in-office phlebotomy, HelioLiver is now more accessible than ever before. This is a meaningful step forward in helping detect liver cancer earlier — when it matters most. Learn more: https://lnkd.in/eDMnUHhr

Closing the gap in HCC surveillance Published data suggests that most liver cancers are diagnosed too late - when survival rates can drop to 4–13%. When detected early, survival can increase to up to 80%. That gap is exactly where we need to improve. Current surveillance approaches face real challenges: • Limited sensitivity for early-stage disease • Low patient adherence • Variability in real-world practice What if we could do better? On April 17, we’re hosting a webinar to explore how emerging blood-based approaches may support earlier detection and more informed clinical decision-making. We’ll cover: • Clinical performance data • Real-world implementation • Case-based insights If this is relevant to your practice, you can register here: 👉 https://lnkd.in/esEGdGbV